This prognostic niche is not unique and has been similarly utilized in other types of malignancies, such as AML, in which molecular markers such as FLT3 and NPM1 risk-stratify patients with normal cytogenetics and normal molecular cytogenetics (50). The gene discussed is FLT3; the disease is acute myeloid leukemia.